FDA approves new treatment for late-stage breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm

Source: Food and Drug Administration - February 22, 2013 Category: American Health Source Type: news